After a bumpy road from its announcement in March 2022, Germany’s Government approved a cost-containment bill in the final quarter of 2022.

The bill faced opposition from many important stakeholders, with objections from doctors and pharmacies as well as pharmaceutical and insurance companies. But now that the bill has passed, what are the implications for Health Technology Assessment (HTA) in Germany? And how do these changes interact with the new European Regulation on HTA?

Lumanity experts Suzette Matthijsse, Ron Akehurst and Daniel Gladwell collaborated with Jürgen Wasem, former chairperson of the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) Drug Price Arbitration Board, to pen a paper which summarises the key points of the Bill and reflects their collective consensus on what these changes mean.

Fill out the form on the right to download the paper.

More from Lumanity on the EU HTA Regulation

Want to find out more about the EU HTA Regulation and how it will affect pharmaceutical companies bringing new products to market in Europe? Head over to Lumanity’s dedicated webpage where you can find all our updates on the Regulation so far, as well as key contacts and details of our training program.

Download the pdf

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
This field is for validation purposes and should be left unchanged.